Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADC Therapeutics SAADCT · Entity 6502 | Director | June 01, 2026 | June 03, 2026 |
| FATE THERAPEUTICS INCFATE · Entity 5968 | Director | June 07, 2024 | June 11, 2024 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Chief Financial Officer | February 06, 2017 | February 09, 2017 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director | June 12, 2026 | June 16, 2026 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | Director | June 09, 2026 | June 10, 2026 |
| aTYR PHARMA INCATYR · Entity 7233 | Director | May 11, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADC Therapeutics SA
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 72,400 |
Ending reported balance
After 2026-06-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-01 · Grant · Acquired 45,000 · Balance 85,000 F1: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-06-03 · Tax withholding · Disposed 12,600 · Balance 72,400 F2: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted.
FATE THERAPEUTICS INC
Report date June 07, 2024 · Filed June 11, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.68 · Expires 2034-06-07 | Direct | 40,000 |
Reported balance
After 2024-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-07 · Grant · Acquired 40,000 · Balance 40,000 F1: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.
F2: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.
NEUROCRINE BIOSCIENCES INC
Report date February 06, 2017 · Filed February 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 137,961 |
Reported balance
After 2017-02-06 transaction · row 1
1 source rowRow 1 · 2017-02-06 · Sale · Disposed 963 · Balance 137,961 F1: Sale of 963 shares of common stock issued upon vesting of 2550 restricted stock units to cover withholding taxes with the balance of the shares (1587) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of 963 shares of common stock issued upon vesting of 2550 restricted stock units to cover withholding taxes with the balance of the shares (1587) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.69 to $43.37. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Travere Therapeutics, Inc.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,250 |
Ending reported balance
After 2026-06-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-12 · Exercise / conversion · Acquired 10,000 · Balance 66,250 Row 2 · 2026-06-12 · Sale · Disposed 10,000 · Balance 56,250 F1: This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2: The weighted average sale price for the transaction reported was $50.0747, and the range of prices were between $50.00 and $50.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.52 · Expires 2028-05-08 | Direct | 0 |
Reported balance
After 2026-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-12 · Exercise / conversion · Disposed 10,000 · Balance 0 F3: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2: The weighted average sale price for the transaction reported was $50.0747, and the range of prices were between $50.00 and $50.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3: The stock option is fully vested and exercisable.
Vir Biotechnology, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,000 |
Ending reported balance
After 2026-06-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-09 · Grant · Acquired 8,000 · Balance 8,000 F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2: 1/3 of the RSUs will vest on June 9, 2027, and the remaining RSUs will vest in two equal annual installments thereafter. Row 2 · 2026-06-09 · Grant · Acquired 8,000 · Balance 16,000 F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F3: The RSUs will vest in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.51 · Expires 2036-06-08 | Direct | 16,000 |
Reported balance
After 2026-06-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-09 · Grant · Acquired 16,000 · Balance 16,000 F4: 1/3 of the shares subject to the stock option will vest and become exercisable on June 9, 2027, and the remaining shares will vest and become exercisable in 24 equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.51 · Expires 2036-06-08 | Direct | 16,000 |
Reported balance
After 2026-06-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-09 · Grant · Acquired 16,000 · Balance 16,000 F5: The shares subject to the stock option vest and become exercisable in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
F2: 1/3 of the RSUs will vest on June 9, 2027, and the remaining RSUs will vest in two equal annual installments thereafter.
F3: The RSUs will vest in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders.
F4: 1/3 of the shares subject to the stock option will vest and become exercisable on June 9, 2027, and the remaining shares will vest and become exercisable in 24 equal monthly installments thereafter.
F5: The shares subject to the stock option vest and become exercisable in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders.
aTYR PHARMA INC
Report date May 11, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-05-11 | Direct | 50,000 |
Reported balance
After 2026-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-11 · Grant · Acquired 50,000 · Balance 50,000 F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 16, 2026 20:46 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $26.52 | $0.00 |
DisclosureSEC source: 0001376043-26-000010 · form4-06162026_080644.xml · derivative · entry 3 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:46 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 10,000 | $50.07 | $500,747.00 |
DisclosureSEC source: 0001376043-26-000010 · form4-06162026_080644.xml · nonDerivative · entry 2 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,250 F1 · kind: This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2 · price: The weighted average sale price for the transaction reported was $50.0747, and the range of prices were between $50.00 and $50.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| June 12, 2026 Filed Jun 16, 2026 20:46 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $26.52 | $265,200.00 |
DisclosureSEC source: 0001376043-26-000010 · form4-06162026_080644.xml · nonDerivative · entry 1 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 22:21 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $8.51 | $0.00 |
DisclosureSEC source: 0001628280-26-042326 · wk-form4_1781130089.xml · derivative · entry 4 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2036-06-08 F5 · derivative.exercise_date: The shares subject to the stock option vest and become exercisable in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 22:21 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $8.51 | $0.00 |
DisclosureSEC source: 0001628280-26-042326 · wk-form4_1781130089.xml · derivative · entry 3 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2036-06-08 F4 · derivative.exercise_date: 1/3 of the shares subject to the stock option will vest and become exercisable on June 9, 2027, and the remaining shares will vest and become exercisable in 24 equal monthly installments thereafter. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 22:21 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-042326 · wk-form4_1781130089.xml · nonDerivative · entry 2 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F3 · shares: The RSUs will vest in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 22:21 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-042326 · wk-form4_1781130089.xml · nonDerivative · entry 1 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2 · shares: 1/3 of the RSUs will vest on June 9, 2027, and the remaining RSUs will vest in two equal annual installments thereafter. Read SEC document |
| June 03, 2026 Filed Jun 3, 2026 21:02 UTC | ADC Therapeutics SA ADCT · Entity 6502 | Tax withholdingCommon Shares | 12,600 | $3.08 | $38,808.00 |
DisclosureSEC source: 0001628280-26-040487 · wk-form4_1780520520.xml · nonDerivative · entry 2 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,400 F2 · kind: Represents the number of Common Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted share units previously granted. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:02 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-040487 · wk-form4_1780520520.xml · nonDerivative · entry 1 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 F1 · shares: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest on the earlier of (i) one year from the grant date or (ii) the date of the 2027 Annual Meeting of Shareholders, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 12,000 | $0.00 Strike: $42.26 | $0.00 |
DisclosureSEC source: 0001376043-26-000006 · form4-05212026_050506.xml · derivative · entry 2 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2036-05-19 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 19, 2026 Filed May 21, 2026 21:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001376043-26-000006 · form4-05212026_050506.xml · nonDerivative · entry 1 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,250 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 3,250 | $43.49 | $141,342.50 |
DisclosureSEC source: 0001376043-26-000005 · form4-05192026_040501.xml · nonDerivative · entry 1 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,250 F1 · kind: This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:17 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001376043-26-000003 · ownership.xml · derivative · entry 1 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-05-11 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionDirector stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001376043-25-000004 · form4-11042025_041110.xml · derivative · entry 5 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionDirector stock option (right to buy) · Derivative | 8,000 | $0.00 Strike: $16.33 | $0.00 |
DisclosureSEC source: 0001376043-25-000004 · form4-11042025_041110.xml · derivative · entry 4 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2026-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 18,000 | $35.03 | $630,601.20 |
DisclosureSEC source: 0001376043-25-000004 · form4-11042025_041110.xml · nonDerivative · entry 3 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,500 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2 · price: The weighted average sale price for the transaction reported was $35.0334, and the range of prices were between $35.00 and $35.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $17.44 | $174,400.00 |
DisclosureSEC source: 0001376043-25-000004 · form4-11042025_041110.xml · nonDerivative · entry 2 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 8,000 | $16.33 | $130,640.00 |
DisclosureSEC source: 0001376043-25-000004 · form4-11042025_041110.xml · nonDerivative · entry 1 Coughlin Timothy · CIK 0001376043 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:13 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantStock Options (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001628280-25-029742 · wk-form4_1749157954.xml · derivative · entry 2 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Shares · 80,000 shares Expires 2035-06-05 F2 · derivative.exercise_date: Represents a one-time initial stock option award made under the Issuer's 2019 Equity Incentive Plan. The options vest over four years from June 3, 2025, with 1/4 vesting on the first anniversary of such date, and the remainder vesting monthly in 36 equal installments, subject to continued service through each such vesting date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 21:13 UTC | ADC Therapeutics SA ADCT · Entity 6502 | GrantCommon Shares | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-029742 · wk-form4_1749157954.xml · nonDerivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 F1 · shares: Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 15, 2025 Filed May 16, 2025 23:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 19,500 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001415889-25-013498 · form4-05162025_070507.xml · derivative · entry 2 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2035-05-15 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 15, 2025 Filed May 16, 2025 23:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-013498 · form4-05162025_070507.xml · nonDerivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,500 F1 · shares: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 01, 2025 Filed May 2, 2025 21:16 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0000950170-25-062932 · ownership.xml · derivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-01 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 1, 2026 or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:29 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0000950170-24-071950 · ownership.xml · derivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2034-06-07 F1 · kind: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 7, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:21 UTC | aTYR PHARMA INC LIFE · Entity 7233 | PurchaseCommon Stock | 50,000 | $1.75 | $87,500.00 |
DisclosureSEC source: 0000950170-24-067989 · ownership.xml · nonDerivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 56,000 F1 · price: Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.665 to $1.80 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: These shares are owned by the Coughlin Family Trust u/a DTD 12/07/2006. The Reporting Person and his spouse serve as co-trustees of the Coughlin Family Trust u/a DTD 12/07/2006. The Reporting Person may be deemed to be the beneficial owner of the securities held by the Coughlin Family Trust u/a DTD 12/07/2006. Read SEC document |
| May 22, 2024 Filed May 23, 2024 23:07 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0000950170-24-064199 · ownership.xml · derivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 22, 2025 or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 19,500 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001415889-24-012846 · form4-05102024_040522.xml · derivative · entry 2 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2034-05-07 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 08, 2024 Filed May 10, 2024 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012846 · form4-05102024_040522.xml · nonDerivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,000 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| June 06, 2023 Filed Jun 7, 2023 20:06 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $5.52 | $0.00 |
DisclosureSEC source: 0001209191-23-035044 · doc4.xml · derivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-06-06 F1 · kind: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders. F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 6, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 13,500 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-23-030958 · doc4.xml · derivative · entry 2 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2033-05-16 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030958 · doc4.xml · nonDerivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:27 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-23-031008 · doc4.xml · derivative · entry 3 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2033-05-17 F2 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 17, 2024 or (ii) the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:27 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031008 · doc4.xml · nonDerivative · entry 2 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 6,000 F1 · ownership.nature: These shares are owned by the Coughlin Family Trust u/a DTD 12/07/2006. The Reporting Person and his spouse serve as co-trustees of the Coughlin Family Trust u/a DTD 12/07/2006. The Reporting Person may be deemed to be the beneficial owner of the securities held by the Coughlin Family Trust u/a DTD 12/07/2006. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:27 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031008 · doc4.xml · nonDerivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:51 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026062 · doc4.xml · derivative · entry 2 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: RSUs convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs fully vested one year from the grant date which was April 26, 2022. F3 · derivative.expiration_date: The RSUs fully vested one year from the grant date which was April 26, 2022. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:51 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionCommon stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-026062 · doc4.xml · nonDerivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on April 26, 2022. F2 · price: RSUs convert into common stock on a one-for-one basis. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:39 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 11,893 | $0.00 Strike: $23.48 | $0.00 |
DisclosureSEC source: 0001209191-22-036343 · doc4.xml · derivative · entry 3 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,893 Underlying: Common Stock · 11,893 shares Expires 2032-06-09 F4 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 9, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:39 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 8,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036343 · doc4.xml · nonDerivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,892 F1 · security: Award of restricted stock units that vest in full on the earlier of (i) June 9, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 20:43 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | SaleCommon Stock | 1,439 | $22.81 | $32,823.59 |
DisclosureSEC source: 0001209191-22-034541 · doc4.xml · nonDerivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,632 F1 · kind: Required number of shares sold by the reporting person to cover tax obligations in connection with the vesting of 2,681 shares of Common Stock underlying RSUs granted to the reporting person on June 2, 2021. This sale was made pursuant to an irrevocable election by the reporting person to satisfy tax obligations through a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: Represents the weighted average sale price of the shares sold from $22.53 to $22.95 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2. Read SEC document |
| May 11, 2022 Filed May 13, 2022 00:22 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001209191-22-028690 · doc4.xml · derivative · entry 2 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-05-10 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 11, 2022 Filed May 13, 2022 00:22 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-028690 · doc4.xml · nonDerivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 23:42 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026087 · doc4.xml · derivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs, granted pursuant to the Issuer's non-employee director compensation policy, vest in full on the earlier of (i) April 26, 2023 or (ii) the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. F2 · derivative.expiration_date: The RSUs, granted pursuant to the Issuer's non-employee director compensation policy, vest in full on the earlier of (i) April 26, 2023 or (ii) the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:33 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantStock Option (Right to Buy) · Derivative | 4,334 | $0.00 Strike: $68.94 | $0.00 |
DisclosureSEC source: 0000899243-21-022090 · doc4.xml · derivative · entry 2 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,334 Underlying: Common Stock · 4,334 shares Expires 2031-06-01 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable on the earlier of (i) June 2, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:33 UTC | FATE THERAPEUTICS INC FATE · Entity 5968 | GrantCommon Stock | 2,681 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-022090 · doc4.xml · nonDerivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,071 F1 · security: Award of restricted stock units that vest in full on the earlier of (i) June 2, 2022 or (ii) the date of the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| May 14, 2021 Filed May 19, 2021 01:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantStock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $18.27 | $0.00 |
DisclosureSEC source: 0001209191-21-033855 · doc4.xml · derivative · entry 2 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-05-13 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · derivative.exercise_date: The equity award vests over a one year period. Read SEC document |
| May 14, 2021 Filed May 19, 2021 01:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033855 · doc4.xml · nonDerivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 F1 · security: Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program. F2 · shares: The equity award vests over a one year period. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 00:06 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 1,428 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001209191-21-029119 · doc4.xml · derivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428 Underlying: Common Stock · 1,428 shares Expires 2031-04-28 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) April 28, 2022 or (ii) the Issuer's 2022 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 9,000 | $0.00 Strike: $15.43 | $0.00 |
DisclosureSEC source: 0001209191-20-030746 · doc4.xml · derivative · entry 2 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2030-05-14 Read SEC document |
| May 15, 2020 Filed May 20, 2020 00:00 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-030746 · doc4.xml · nonDerivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Read SEC document |
| May 06, 2020 Filed May 8, 2020 20:53 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 1,428 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001209191-20-027960 · doc4.xml · derivative · entry 1 COUGHLIN TIMOTHY · CIK 0001376043 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428 Underlying: Common Stock · 1,428 shares Expires 2030-05-06 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 6, 2021 or (ii) the Issuer's 2021 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.